APO RESEARCH · REPORT
Oncolytic Virus Therapy
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
Product & engineering
Understand the product.
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
Selected research
Industry Research
Oncolytic Virus Therapy Industry Research Report 2026
Market perspective
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
Amgen, Colytics Biotech, Iralytics and Ransgene SA are the leading providers of oncolytic virus therapy, with the first 3 accounting for about 60% of the market.
North America and Europe are the main markets, each accounting for about 40% of the market.
Read the full market overview
Report Scope
This report quantifies the global Oncolytic Virus Therapy market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Oncolytic Virus Therapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oncolytic Virus Therapy Market by Company
Amgen
Oncolytics Biotech
Viralytics
Transgene SA
Oncolys BioPharma
Targovax
PsiOxus Therapeutics
SillaJen Biotherapeutics
Sorrento Therapeutics
Lokon Pharma
Genelux Corporation
Vyriad
TILT Biotherapeutics
Cold Genesys
Oncolytic Virus Therapy Segment by Type
HSV-based Oncolytic Viruses
Adenoviruses-based Oncolytic Viruses
Vaccinia Virus-based Oncolytic Viruses
Vesicular Stomatitis Virus-based Oncolytic Viruses
Newcastle Disease Virus-based Oncolytic Viruses
Oncolytic Virus Therapy Segment by Application
Melanoma
Prostate Cancer
Breast Cancer
Ovarian Cancer
Others
Oncolytic Virus Therapy Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncolytic Virus Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncolytic Virus Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncolytic Virus Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oncolytic Virus Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- HSV-based Oncolytic Viruses
- Adenoviruses-based Oncolytic Viruses
- Vaccinia Virus-based Oncolytic Viruses
- Vesicular Stomatitis Virus-based Oncolytic Viruses
- Newcastle Disease Virus-based Oncolytic Viruses
Applications
- Melanoma
- Prostate Cancer
- Breast Cancer
- Ovarian Cancer
- Others
Companies covered
- Amgen
- Oncolytics Biotech
- Viralytics
- Transgene SA
- Oncolys BioPharma
- Targovax
- PsiOxus Therapeutics
- SillaJen Biotherapeutics
- Sorrento Therapeutics
- Lokon Pharma
- Genelux Corporation
- Vyriad
- TILT Biotherapeutics
- Cold Genesys
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Oncolytic Virus Therapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 HSV-based Oncolytic Viruses
- 2.2.3 Adenoviruses-based Oncolytic Viruses
- 2.2.4 Vaccinia Virus-based Oncolytic Viruses
- 2.2.5 Vesicular Stomatitis Virus-based Oncolytic Viruses
- 2.2.6 Newcastle Disease Virus-based Oncolytic Viruses
- 2.3 Oncolytic Virus Therapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Melanoma
- 2.3.3 Prostate Cancer
- 2.3.4 Breast Cancer
- 2.3.5 Ovarian Cancer
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Oncolytic Virus Therapy Breakdown Data by Type
- 3.1 Global Oncolytic Virus Therapy Historic Market Size by Type (2021-2026)
- 3.2 Global Oncolytic Virus Therapy Forecasted Market Size by Type (2027-2032)
4 Oncolytic Virus Therapy Breakdown Data by Application
- 4.1 Global Oncolytic Virus Therapy Historic Market Size by Application (2021-2026)
- 4.2 Global Oncolytic Virus Therapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Oncolytic Virus Therapy Market Perspective (2021-2032)
- 5.2 Global Oncolytic Virus Therapy Growth Trends by Region
- 5.2.1 Global Oncolytic Virus Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Oncolytic Virus Therapy Historic Market Size by Region (2021-2026)
- 5.2.3 Oncolytic Virus Therapy Forecasted Market Size by Region (2027-2032)
- 5.3 Oncolytic Virus Therapy Market Dynamics
- 5.3.1 Oncolytic Virus Therapy Industry Trends
- 5.3.2 Oncolytic Virus Therapy Market Drivers
- 5.3.3 Oncolytic Virus Therapy Market Challenges
- 5.3.4 Oncolytic Virus Therapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Oncolytic Virus Therapy Players by Revenue
- 6.1.1 Global Top Oncolytic Virus Therapy Players by Revenue (2021-2026)
- 6.1.2 Global Oncolytic Virus Therapy Revenue Market Share by Players (2021-2026)
- 6.2 Global Oncolytic Virus Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Oncolytic Virus Therapy Head Office and Area Served
- 6.4 Global Oncolytic Virus Therapy Players, Product Type & Application
- 6.5 Global Oncolytic Virus Therapy Manufacturers Established Date
- 6.6 Global Oncolytic Virus Therapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Oncolytic Virus Therapy Market Size (2021-2032)
- 7.2 North America Oncolytic Virus Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Oncolytic Virus Therapy Market Size by Country (2021-2026)
- 7.4 North America Oncolytic Virus Therapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Oncolytic Virus Therapy Market Size (2021-2032)
- 8.2 Europe Oncolytic Virus Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Oncolytic Virus Therapy Market Size by Country (2021-2026)
- 8.4 Europe Oncolytic Virus Therapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Oncolytic Virus Therapy Market Size (2021-2032)
- 9.2 Asia-Pacific Oncolytic Virus Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Oncolytic Virus Therapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Oncolytic Virus Therapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Oncolytic Virus Therapy Market Size (2021-2032)
- 10.2 South America Oncolytic Virus Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Oncolytic Virus Therapy Market Size by Country (2021-2026)
- 10.4 South America Oncolytic Virus Therapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Oncolytic Virus Therapy Market Size (2021-2032)
- 11.2 Middle East & Africa Oncolytic Virus Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Oncolytic Virus Therapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Oncolytic Virus Therapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Amgen
- 12.1.1 Amgen Company Information
- 12.1.2 Amgen Business Overview
- 12.1.3 Amgen Revenue in Oncolytic Virus Therapy Business (2021-2026)
- 12.1.4 Amgen Oncolytic Virus Therapy Product Portfolio
- 12.1.5 Amgen Recent Developments
- 12.2 Oncolytics Biotech
- 12.2.1 Oncolytics Biotech Company Information
- 12.2.2 Oncolytics Biotech Business Overview
- 12.2.3 Oncolytics Biotech Revenue in Oncolytic Virus Therapy Business (2021-2026)
- 12.2.4 Oncolytics Biotech Oncolytic Virus Therapy Product Portfolio
- 12.2.5 Oncolytics Biotech Recent Developments
- 12.3 Viralytics
- 12.3.1 Viralytics Company Information
- 12.3.2 Viralytics Business Overview
- 12.3.3 Viralytics Revenue in Oncolytic Virus Therapy Business (2021-2026)
- 12.3.4 Viralytics Oncolytic Virus Therapy Product Portfolio
- 12.3.5 Viralytics Recent Developments
- 12.4 Transgene SA
- 12.4.1 Transgene SA Company Information
- 12.4.2 Transgene SA Business Overview
- 12.4.3 Transgene SA Revenue in Oncolytic Virus Therapy Business (2021-2026)
- 12.4.4 Transgene SA Oncolytic Virus Therapy Product Portfolio
- 12.4.5 Transgene SA Recent Developments
- 12.5 Oncolys BioPharma
- 12.5.1 Oncolys BioPharma Company Information
- 12.5.2 Oncolys BioPharma Business Overview
- 12.5.3 Oncolys BioPharma Revenue in Oncolytic Virus Therapy Business (2021-2026)
- 12.5.4 Oncolys BioPharma Oncolytic Virus Therapy Product Portfolio
- 12.5.5 Oncolys BioPharma Recent Developments
- 12.6 Targovax
- 12.6.1 Targovax Company Information
- 12.6.2 Targovax Business Overview
- 12.6.3 Targovax Revenue in Oncolytic Virus Therapy Business (2021-2026)
- 12.6.4 Targovax Oncolytic Virus Therapy Product Portfolio
- 12.6.5 Targovax Recent Developments
- 12.7 PsiOxus Therapeutics
- 12.7.1 PsiOxus Therapeutics Company Information
- 12.7.2 PsiOxus Therapeutics Business Overview
- 12.7.3 PsiOxus Therapeutics Revenue in Oncolytic Virus Therapy Business (2021-2026)
- 12.7.4 PsiOxus Therapeutics Oncolytic Virus Therapy Product Portfolio
- 12.7.5 PsiOxus Therapeutics Recent Developments
- 12.8 SillaJen Biotherapeutics
- 12.8.1 SillaJen Biotherapeutics Company Information
- 12.8.2 SillaJen Biotherapeutics Business Overview
- 12.8.3 SillaJen Biotherapeutics Revenue in Oncolytic Virus Therapy Business (2021-2026)
- 12.8.4 SillaJen Biotherapeutics Oncolytic Virus Therapy Product Portfolio
- 12.8.5 SillaJen Biotherapeutics Recent Developments
- 12.9 Sorrento Therapeutics
- 12.9.1 Sorrento Therapeutics Company Information
- 12.9.2 Sorrento Therapeutics Business Overview
- 12.9.3 Sorrento Therapeutics Revenue in Oncolytic Virus Therapy Business (2021-2026)
- 12.9.4 Sorrento Therapeutics Oncolytic Virus Therapy Product Portfolio
- 12.9.5 Sorrento Therapeutics Recent Developments
- 12.10 Lokon Pharma
- 12.10.1 Lokon Pharma Company Information
- 12.10.2 Lokon Pharma Business Overview
- 12.10.3 Lokon Pharma Revenue in Oncolytic Virus Therapy Business (2021-2026)
- 12.10.4 Lokon Pharma Oncolytic Virus Therapy Product Portfolio
- 12.10.5 Lokon Pharma Recent Developments
- 12.11 Genelux Corporation
- 12.11.1 Genelux Corporation Company Information
- 12.11.2 Genelux Corporation Business Overview
- 12.11.3 Genelux Corporation Revenue in Oncolytic Virus Therapy Business (2021-2026)
- 12.11.4 Genelux Corporation Oncolytic Virus Therapy Product Portfolio
- 12.11.5 Genelux Corporation Recent Developments
- 12.12 Vyriad
- 12.12.1 Vyriad Company Information
- 12.12.2 Vyriad Business Overview
- 12.12.3 Vyriad Revenue in Oncolytic Virus Therapy Business (2021-2026)
- 12.12.4 Vyriad Oncolytic Virus Therapy Product Portfolio
- 12.12.5 Vyriad Recent Developments
- 12.13 TILT Biotherapeutics
- 12.13.1 TILT Biotherapeutics Company Information
- 12.13.2 TILT Biotherapeutics Business Overview
- 12.13.3 TILT Biotherapeutics Revenue in Oncolytic Virus Therapy Business (2021-2026)
- 12.13.4 TILT Biotherapeutics Oncolytic Virus Therapy Product Portfolio
- 12.13.5 TILT Biotherapeutics Recent Developments
- 12.14 Cold Genesys
- 12.14.1 Cold Genesys Company Information
- 12.14.2 Cold Genesys Business Overview
- 12.14.3 Cold Genesys Revenue in Oncolytic Virus Therapy Business (2021-2026)
- 12.14.4 Cold Genesys Oncolytic Virus Therapy Product Portfolio
- 12.14.5 Cold Genesys Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst